NCT01860326View on ClinicalTrials.gov

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Hepatic Insufficiency
Interventions
DRUG

Alisporivir

Capsules supplied as open labeled bulk medication in 10-unit blister packages

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY